SCHOTT & Serum Institute announce JV for pharmaceutical packaging

Serum Institute of India (SII) acquires 50% stake of SCHOTT Kaisha to become SCHOTT’s joint venture partner and secure pharma packaging supply

0
83
An employee at SCHOTT Kaisha’s production facility in Jambusar inspects two glass vials. Image: SCHOTT/Alexander Sell
New Delhi/Pune: Germany’s specialty glass company, SCHOTT AG has a new partner: Serum Institute of India, the world‘s largest vaccine producer and manufacturer of highly-effective biologics, has bought the 50% stake in the Indian joint venture SCHOTT Kaisha from former co-owners Kairus Dadachanji and Shapoor Mistry. The joint venture is the leading Indian manufacturer of pharma packaging products such as vials, syringes, ampoules and cartridges used to package life-saving medications. With this acquisition, Serum is securing its supply of high-quality pharma packaging amid rising global demand.
Adar Poonawalla, CEO Serum Institute of India says, “Even the best medication can’t
reach the patient without the right packaging. Securing this supply chain is of strategic
importance. SCHOTT is the perfect partner for us to do this because of their expertise and
global network. As a longtime customer, we use their vials, ampoules and syringes to store
our vaccines including COVISHIELD™. Working even closer together is in the best interest
of global health.”
SCHOTT is looking forward to the cooperation with the new partner. Dr. Frank Heinricht,
CEO SCHOTT says, “As India has steadily established its position as a global
pharmaceutical hub, we are delighted to strengthen our footprint within the Indian pharma
supply chain. We are looking forward to strong impulses from this partnership. It is an
excellent example of shifting towards new cooperation models, with greater synergies
between pharma manufacturing and packaging production.”
The joint venture will definitely continue to supply its customers in India and abroad as a
reliable partner, says Eric L’Heureux, the new Managing Director and former
longstanding Head of Operations. “We have significantly increased our production
capacity in India. Over the last three years we have invested roughly INR 600 crores to set
up two new plants in Umarsadi, Gujarat and Baddi, Himachal Pradesh, and to secure
uninterrupted supply in our existing facilities during the pandemic.” Both SCHOTT and
Serum are committed to invest further and will announce concrete plans as this partnership
evolves.
Fighting COVID-19 together
Working together in the joint venture opens a new chapter in the successful partnership of
Serum and SCHOTT. The companies have had a strong business relationship – and both
have been playing a crucial role during the pandemic. From the onset of the COVID-19
outbreak Serum rose to the challenge of developing and/or manufacturing live-saving vaccines, such as COVISHIELD and COVOVAX. To this day, the company has filled and
delivered hundreds of millions of doses to India and the world.
On the packaging end, SCHOTT has already exceeded its target to deliver vials for more
than 2 billion vaccine doses through 2021. The company is providing glass vials globally to
key vaccine manufacturers. The fact that SCHOTT has an integrated value chain, covering
also the glass tubing the packaging is made of, further helped to secure the supply chain.